Back to News
Market Impact: 0.35
AstraZeneca's Enhertu, Klygefa Get Positive CHMP Opinions In EU
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
AstraZeneca said the European Medicines Agency's CHMP recommended approval of Enhertu in an additional early breast cancer setting and Alexion's Klygefa for adults with a generalized condition. The positive CHMP opinions could expand the companies' addressable treatment populations, subject to final European Commission approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
AZN0.68
More News
- Enhertu recommended for approval in EU in early BC
- Europe’s STOXX 600 gains as tech rallies, oil retreat eases nerves
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros